Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Inflammatory Bowel Diseases

Free Subscription Articles published in Gastroenterol Hepatol Retrieve available abstracts of 100 articles: HTML format

Single Articles

October 2025
1. MADERO L, Baston I, Brunet-Mas E, Calafat M, et al
   TUBERCULOSIS AND INFLAMMATORY BOWEL DISEASE.
   Gastroenterol Hepatol. 2025 Oct 14:502587. doi: 10.1016/j.gastrohep.2025.502587.
   PubMed     Abstract available
   
   
   
2. JIANG P, Li Y, Tian J, Luo Y, et al
   Efficacy and safety of biologic therapy for Crohn's disease: An overview of meta-analyses and systematic reviews.
   Gastroenterol Hepatol. 2025;48:502432.
   PubMed     Abstract available
   
   
   September 2025
3. ROCHE PC, Casanovas-Marsal JO, Lopez SG, Lidon RV, et al
   TRANSLATION AND PSYCHOMETRIC EVALUATION OF THE SPANISH VERSION OF THE INFLAMMATORY BOWEL DISEASE KNOWLEDGE (IBD-KNOW) QUESTIONNAIRE.
   Gastroenterol Hepatol. 2025 Sep 9:502576. doi: 10.1016/j.gastrohep.2025.502576.
   PubMed     Abstract available
   
   
   
4. LOPEZ-CALLEJA AM, Cauce BL, Colomino MI, Martin BV, et al
   Fatigue in patients with Inflammatory Bowel Disease: a descriptive cross-sectional study.
   Gastroenterol Hepatol. 2025 Sep 7:502557. doi: 10.1016/j.gastrohep.2025.502557.
   PubMed     Abstract available
   
   
   August 2025
5. ELOSUA A, Nantes O, Chaparro M, Zabalza L, et al
   Early Advanced Therapies and Real-World Outcomes in Crohn's Disease: A Population-Based Comparison of Two Incident Cohorts in Navarra.
   Gastroenterol Hepatol. 2025 Aug 31:502540. doi: 10.1016/j.gastrohep.2025.502540.
   PubMed     Abstract available
   
   
   
6. RODRIGUEZ-LAGO I, Casas-Deza D, Rimola J, Calafat M, et al
   Spanish Working Group in Crohn's Disease and Ulcerative Colitis (GETECCU) position paper for the management of non-perianal fistulizing Crohn's disease.
   Gastroenterol Hepatol. 2025;48:502450.
   PubMed     Abstract available
   
   
   
7. CARVAJAL F, Herrera K, Nunez P, Flores L, et al
   Evaluation of remission in ulcerative colitis: Relationship between clinical, endoscopic, and histological markers as predictors of relapse.
   Gastroenterol Hepatol. 2025;48:502437.
   PubMed     Abstract available
   
   
   
8. ANDRES L, Iborra M, Vicente R, Arias L, et al
   High persistence rate at one year- follow-up of subcutaneous vedolizumab at standard dose after switching endovenous vedolizumab, even in those previously intensified: results of a Spanish multicentre observational study.
   Gastroenterol Hepatol. 2025;48:502379.
   PubMed     Abstract available
   
   
   July 2025
9. JULIAO-BANOS F, Parra-Izquierdo V, Pacheco T, Leano JTA, et al
   Epidemiology and Healthcare Resource Utilization in Inflammatory Bowel Disease in Colombia between 2017-2021: A Retrospective Claims Database Study.
   Gastroenterol Hepatol. 2025 Jul 16:502532. doi: 10.1016/j.gastrohep.2025.502532.
   PubMed     Abstract available
   
   
   
10. PINERO G, Castillo E, Gonzalez-Munoza C, Calm A, et al
    Predictors of early immunosuppression at ulcerative colitis onset in the biological era.
    Gastroenterol Hepatol. 2025 Jul 16:502533. doi: 10.1016/j.gastrohep.2025.502533.
    PubMed     Abstract available
    
    
    
11. MANOSA M, Calafat M, Francia E, Riba F, et al
    GETECCU POSITION PAPER ON FRAGILITY, ADVANCED AGE AND INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2025 Jul 12:502529. doi: 10.1016/j.gastrohep.2025.502529.
    PubMed     Abstract available
    
    
    
12. CASELLAS F, Gutierrez-Casbas A, Rodriguez C, Gisbert JP, et al
    EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumor necrosis factor-alpha as first- or second-line biologic treatment among patients with ulcerative colitis.
    Gastroenterol Hepatol. 2025 Jul 11:502528. doi: 10.1016/j.gastrohep.2025.502528.
    PubMed     Abstract available
    
    
    June 2025
13. GISBERT JP, Chaparro M
    Etrasimod: Review of the efficacy and therapeutic prospects of a new oral therapy for the treatment of ulcerative colitis.
    Gastroenterol Hepatol. 2025;48:502363.
    PubMed     Abstract available
    
    
    
14. ROBLES-ALONSO V, Solans R, Lastiri E, Serra X, et al
    Antiphospholipid syndrome autoantibodies induction after treatment with anti-TNF alpha therapy in patients with IBD.
    Gastroenterol Hepatol. 2025;48:502258.
    PubMed     Abstract available
    
    
    May 2025
15. HERRERO-RODRIGUEZ S, Martin-Cordero L, Mayordomo R, Galvez I, et al
    Sex-based differences in the relationship between health-related quality of life, physical activity, and inflammatory markers in people with Crohn's disease.
    Gastroenterol Hepatol. 2025 May 30:502494. doi: 10.1016/j.gastrohep.2025.502494.
    PubMed     Abstract available
    
    
    
16. INIESTA-NAVALON C, Rentero-Redondo L, Gomez-Espin R, Saorin MR, et al
    Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes "Infliximab trough levels variability in inflammatory bowel disease".
    Gastroenterol Hepatol. 2025 May 23:502472. doi: 10.1016/j.gastrohep.2025.502472.
    PubMed     Abstract available
    
    
    
17. CORREAL EN, Gomez DM, Sequeiros AR, Gonzalo FM, et al
    Insights into the status of the quality of nursing care in patients with inflammatory bowel disease: A nationwide survey (The MAPEA Project).
    Gastroenterol Hepatol. 2025 May 14:502464. doi: 10.1016/j.gastrohep.2025.502464.
    PubMed     Abstract available
    
    
    
18. GIORDANO A, Baston I, Madero L, Brunet-Mas E, et al
    Unraveling the Gut-Fat-Inflammation Connection in Crohn's Disease: A Path to New Therapeutic Targets?
    Gastroenterol Hepatol. 2025 May 14:502466. doi: 10.1016/j.gastrohep.2025.502466.
    PubMed    
    
    
    
19. MINGUEZ A, Coello E, Garrido A, Ripoll P, et al
    Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and adjusted regimen in real world.
    Gastroenterol Hepatol. 2025;48:502253.
    PubMed     Abstract available
    
    
    April 2025
20. CARVAJAL F, Herrera K, Nunez P, Flores L, et al
    CHALLENGES IN ADHERENCE TO STRIDE-II: PERSPECTIVES FROM GASTROENTEROLOGISTS AND PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2025 Apr 3:502440. doi: 10.1016/j.gastrohep.2025.502440.
    PubMed     Abstract available
    
    
    March 2025
21. SAVIO MC, Coelho JC, Oliveira E, Magro DO, et al
    Nationwide Trends in Colectomy Rates for Ulcerative Colitis in Brazil: An Analysis of the Unified Public Healthcare System.
    Gastroenterol Hepatol. 2025 Mar 20:502434. doi: 10.1016/j.gastrohep.2025.502434.
    PubMed     Abstract available
    
    
    
22. GINARD D, Fontanillas N, Baston-Rey I, Pejenaute ME, et al
    Position statement of the Spanish Society of Primary Care Physicians (SEMERGEN) and Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the management of inflammatory bowel disease in Primary Care.
    Gastroenterol Hepatol. 2025;48:502255.
    PubMed     Abstract available
    
    
    February 2025
23. FERREIRA SDC, Parra RS, Sassaki LY, Miguel Luz Parente J, et al
    CLINICAL EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VERSUS INFLIXIMAB IN BIOLOGIC-NAIVE PATIENTS WITH ULCERATIVE COLITIS: A COMPARATIVE REAL-WORLD MULTICENTRIC OBSERVATIONAL STUDY.
    Gastroenterol Hepatol. 2025 Feb 21:502396. doi: 10.1016/j.gastrohep.2025.502396.
    PubMed     Abstract available
    
    
    
24. FONSECA CB, Petry R, Harlacher L, Hanauer L, et al
    Body mass index does not influence loss of response to tumor necrosis factor inhibitors in Crohn's disease.
    Gastroenterol Hepatol. 2025 Feb 4:502372. doi: 10.1016/j.gastrohep.2025.502372.
    PubMed     Abstract available
    
    
    January 2025
25. ZHENG D, Qinke X, Jin W, Zhouyue G, et al
    Prevalence and Bidirectional Association Between Primary Sclerosing Cholangitis and Crohn's disease: A Systematic Review and Meta-Analysis.
    Gastroenterol Hepatol. 2025 Jan 18:502346. doi: 10.1016/j.gastrohep.2025.502346.
    PubMed     Abstract available
    
    
    
26. MORENO ALFONSO JC, Barbosa-Velasquez S, Delgado-Miguel C, Molina Caballero A, et al
    EXPLORING THE UTILITY OF CELLULAR INDICES IN THE DIAGNOSIS OF ULCERATIVE COLITIS.
    Gastroenterol Hepatol. 2025 Jan 17:502349. doi: 10.1016/j.gastrohep.2025.502349.
    PubMed     Abstract available
    
    
    
27. KINOSHITA K, Sawaguchi S, Toyoshima K, Yoshida S, et al
    Novel desensitization therapy of mesalamine intolerance in patients with ulcerative colitis.
    Gastroenterol Hepatol. 2025 Jan 9:502347. doi: 10.1016/j.gastrohep.2025.502347.
    PubMed     Abstract available
    
    
    December 2024
28. PERIS MA, Francisco JDH, Mateu PN, Piudo AE, et al
    Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of Telemedicine in Inflammatory Bowel Disease.
    Gastroenterol Hepatol. 2024 Dec 11:502320. doi: 10.1016/j.gastrohep.2024.502320.
    PubMed     Abstract available
    
    
    
29. GONZALEZ-MUNOZA C, Gely C, Gordillo J, Calafat M, et al
    Perception of the impact of intravenous biological treatment on the work and professional environment in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2024;47:502193.
    PubMed     Abstract available
    
    
    
30. RODRIGUEZ-LAGO I, Herrera-deGuise C, Bosca-Watts M, Rodriguez C, et al
    Combination of granulocyte-monocyte apheresis and ustekinumab: Multicentre and retrospective study.
    Gastroenterol Hepatol. 2024;47:502195.
    PubMed     Abstract available
    
    
    November 2024
31. CARRASCO MF, Fernandez AP, Garcia OS
    Hyperinfestation by strongyloides stercolaris in an immunodepressed patient due to inflammatory bowel disease.
    Gastroenterol Hepatol. 2024 Nov 29:502317. doi: 10.1016/j.gastrohep.2024.502317.
    PubMed    
    
    
    
32. MARIN-JIMENEZ I, Carpio D, Hernandez V, Munoz F, et al
    Spanish Working Group in Crohn s disease and ulcerative colitis (GETECCU) position paper on cardiovascular disease in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2024 Nov 28:502314. doi: 10.1016/j.gastrohep.2024.502314.
    PubMed     Abstract available
    
    
    
33. FARRUKH A, Mayberry JF
    Inflammatory Bowel Disease in the Gypsy Community in England and Scotland.
    Gastroenterol Hepatol. 2024 Nov 22:502295. doi: 10.1016/j.gastrohep.2024.502295.
    PubMed     Abstract available
    
    
    
34. OLIVERA PA, Balderramo DC, Lasa JS, Zubiaurre I, et al
    Real-world clinical characteristics and therapeutic strategies in patients with moderate-to-severe inflammatory bowel disease in Argentina: Data from the RISE-AR study.
    Gastroenterol Hepatol. 2024 Nov 14:502287. doi: 10.1016/j.gastrohep.2024.502287.
    PubMed     Abstract available
    
    
    October 2024
35. RAMOS L, Marin-Jimenez I
    Disease clearance in ulcerative colitis: what is it? What does it involve? How do we translate it into spanish?
    Gastroenterol Hepatol. 2024 Oct 28:502281. doi: 10.1016/j.gastrohep.2024.502281.
    PubMed    
    
    
    
36. SILVA RL, da Silva E Sousa FI, Silva GLFD, Almeida VDR, et al
    The impact of anxiety and depression on quality of life in a cohort of inflammatory bowel disease patients from northeastern of brazil.
    Gastroenterol Hepatol. 2024 Oct 28:502283. doi: 10.1016/j.gastrohep.2024.502283.
    PubMed     Abstract available
    
    
    
37. INIESTA-NAVALON C, Rios-Saorin M, Rentero-Redondo L, Anez-Castano R, et al
    Comparative evaluation of Point of Care assay with ELISA techniques for quantifying serum concentrations of ustekinumab in inflammatory bowel disease patients.
    Gastroenterol Hepatol. 2024 Oct 21:502277. doi: 10.1016/j.gastrohep.2024.502277.
    PubMed     Abstract available
    
    
    
38. OLIVERA PA, Parks ML, Pellegrini D, Finn B, et al
    Incidence and prevalence of inflammatory bowel diseases in a population from Buenos Aires, Argentina.
    Gastroenterol Hepatol. 2024;47:804-812.
    PubMed     Abstract available
    
    
    September 2024
39. FERNANDEZ CARRASCO M, Delgado Maroto A, Hernandez Martinez A
    CEREBRAL THROMBOSIS AS A MANIFESTATION OF POOR CONTROL IN INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2024 Sep 28:502256. doi: 10.1016/j.gastrohep.2024.502256.
    PubMed    
    
    
    
40. RUEDA GARCIA JL, Benitez JM, Baston Rey I, Calafat Sard M, et al
    Thromboembolic phenomena in inflammatory bowel disease and risk with JAK inhibitor treatments.
    Gastroenterol Hepatol. 2024 Sep 19:502257. doi: 10.1016/j.gastrohep.2024.502257.
    PubMed    
    
    
    
41. FISSAH M, Rechach A, Charifi M, Menzou F, et al
    Increased arterial stiffness in Crohn's disease: prevalence, associated factors and impact of anti-TNF therapy.
    Gastroenterol Hepatol. 2024 Sep 11:502252. doi: 10.1016/j.gastrohep.2024.502252.
    PubMed     Abstract available
    
    
    August 2024
42. DIAZ MOLINA RJ, Comesana Castellar C, Crespi Rigo J, Radu Tomsa C, et al
    DESCRIPTIVE OBSERVATIONAL STUDY ON THE USE OF VIRTUAL REALITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNDERGOING BIOLOGICAL TREATMENT.
    Gastroenterol Hepatol. 2024 Aug 20:502236. doi: 10.1016/j.gastrohep.2024.502236.
    PubMed     Abstract available
    
    
    
43. CARLOS GONCALVES J, Arieira C, Xavier S, Magalhaes J, et al
    Small Bowel Crohn's Disease: Proximal Lesions Linked to Increased Inflammation and Biologic Treatment Needs.
    Gastroenterol Hepatol. 2024 Aug 5:502235. doi: 10.1016/j.gastrohep.2024.502235.
    PubMed     Abstract available
    
    
    
44. FRAGA-BLANCO P, Boullon-Batalla N, Benitez JM, Suarez-Ferrer C, et al
    What strategies do we employ in the prevention andmonitoring of human papillomavirus inpatients with inflammatory bowel disease?
    Gastroenterol Hepatol. 2024;47:771-773.
    PubMed    
    
    
    
45. RODRIGUEZ-LAGO I, Canete F, Guerra-Del-Rio E, Herrera-deGuise C, et al
    Combination of granulocyte-monocyte apheresis and tofacitinib: Multicentre and retrospective study.
    Gastroenterol Hepatol. 2024;47:727-733.
    PubMed     Abstract available
    
    
    
46. SUAREZ FERRER C, Martin-Arranz E, Martin-Arranz MD
    Selective granulocyte-monocyte apheresis during induction with vedolizumab in moderate-severe ulcerative colitis: Experience in a tertiary hospital.
    Gastroenterol Hepatol. 2024;47:721-726.
    PubMed     Abstract available
    
    
    
47. LORAS C, Piqueras M, Ruiz P, Zaffalon D, et al
    Duodenal stenosis in a Crohn's disease patient treated with lumen apposing metal stent.
    Gastroenterol Hepatol. 2024;47:759-760.
    PubMed    
    
    
    July 2024
48. CALDERON P, Nunez P, Herrera K, Flores L, et al
    Evaluation of the sensitivity and specificity of sigmoidoscopy in comparison to colonoscopy regarding the detection of intestinal inflammatory activity in the follow-up of patients with ulcerative colitis.
    Gastroenterol Hepatol. 2024 Jul 17:502232. doi: 10.1016/j.gastrohep.2024.502232.
    PubMed     Abstract available
    
    
    
49. VIDAL-DELSO M, Fortuny M, Gonzalez-Gonzalez L, Pelach A, et al
    Strongyloides stercolaris hiperinfection syndrome in ulcerative colitis treated with corticotherapy. The importance of strongyloides screening.
    Gastroenterol Hepatol. 2024 Jul 9:502230. doi: 10.1016/j.gastrohep.2024.502230.
    PubMed    
    
    
    May 2024
50. LOPEZ-SERRANO A, Cabaleiro AV, Ramon Lorente Montoro J, Gomez FJS, et al
    Artificial intelligence for dysplasia detection during surveillance colonoscopy in patients with ulcerative colitis: a cross-sectional, non-inferiority, diagnostic test comparison study.
    Gastroenterol Hepatol. 2024 May 11:502210. doi: 10.1016/j.gastrohep.2024.502210.
    PubMed     Abstract available
    
    
    
51. GRAVINA AG, Pellegrino R, Palladino G, Imperio G, et al
    Profiling the patient with inflammatory bowel disease in the relationship between physical activity and partner/social network status: a post-hoc patient-tailored analysis of the "BE-FIT-IBD" study**.
    Gastroenterol Hepatol. 2024 May 7:502203. doi: 10.1016/j.gastrohep.2024.502203.
    PubMed     Abstract available
    
    
    
52. LAGO IR, Gros B, Sanchez K, Arumi D, et al
    Use of digital health tools in inflammatory bowel disease.
    Gastroenterol Hepatol. 2024 May 7:502200. doi: 10.1016/j.gastrohep.2024.502200.
    PubMed     Abstract available
    
    
    
53. COSTA CA, Ferrer CS, Ramirez LG, Arranz EM, et al
    EVALUATION OF THE TRANSITION FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2024 May 7:502201. doi: 10.1016/j.gastrohep.2024.502201.
    PubMed     Abstract available
    
    
    
54. DA SILVA E SOUSA FI, Silva RL, Rabelo Lemos Filho CN, Pereira Santos MTO, et al
    VACCINE ADHERENCE AND ADVERSE EVENTS OF THE SARS-COV VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2024 May 7:502202. doi: 10.1016/j.gastrohep.2024.502202.
    PubMed     Abstract available
    
    
    
55. CALVO BERNAL MDM, Campos EP, Mota AA, Martinez AH, et al
    ASSESSMENT OF THE QUALITY OF LIFE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2024 May 6:502192. doi: 10.1016/j.gastrohep.2024.502192.
    PubMed     Abstract available
    
    
    
56. RAMOS COZAR SN, Masot RM, Gallego BR, Rubio L, et al
    Assessment of the length of sick leave in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2024 May 5:502194. doi: 10.1016/j.gastrohep.2024.502194.
    PubMed     Abstract available
    
    
    
57. FERNANDEZ-PEREZ FJ, Moreno NF, Lopez ES, Rodriguez-Gonzalez FJ, et al
    GRANULOCYTE AND MONOCYTE ADSORPTIVE APHERESIS (GMA) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A USEFUL THERAPEUTIC TOOL NOT JUST IN ULCERATIVE COLITIS BUT ALSO IN CROHN S DISEASE.
    Gastroenterol Hepatol. 2024 May 4:502196. doi: 10.1016/j.gastrohep.2024.502196.
    PubMed     Abstract available
    
    
    
58. FERRER CS, Gismero FM, Caballol B, Ballester MP, et al
    EFFICACY AND SAFETY OF BIOLOGICAL TREATMENT FOR INFLAMMATORY BOWEL DISEASE IN ELDERLY PATIENTS: RESULTS FROM A GETECCU COHORT.
    Gastroenterol Hepatol. 2024 May 4:502197. doi: 10.1016/j.gastrohep.2024.502197.
    PubMed     Abstract available
    
    
    
59. RODRIGUEZ-MORANTA F, Arguelles-Arias F, Hinojosa Del Val J, Iborra Colomino M, et al
    Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis.
    Gastroenterol Hepatol. 2024;47:522-552.
    PubMed     Abstract available
    
    
    April 2024
60. FUENTES-VALENZUELA E, Carbajo AY, Fernandez-Prada SJ, Rubiales BM, et al
    Beyond Crohn's disease: Deferasirox as possible agent for drug-induced ileocolitis.
    Gastroenterol Hepatol. 2024;47:380-381.
    PubMed    
    
    
    
61. RODRIGUEZ-LAGO I, Abecia L, Seoane I, Anguita J, et al
    An in vitro analysis of the interaction between infliximab and granulocyte-monocyte apheresis.
    Gastroenterol Hepatol. 2024;47:347-351.
    PubMed     Abstract available
    
    
    March 2024
62. NAVARRO-GERRARD C, Calafat M, Benitez JM, Suarez-Ferrer C, et al
    Are biologic agents effective and safe in patients with IBD and solid organ transplantation?
    Gastroenterol Hepatol. 2024;47:289-292.
    PubMed    
    
    
    
63. LASA J, Smolarczuk A, Navar S, Ponce C, et al
    Endoscopic scoring system utilization for inflammatory bowel disease activity assessment: A multicenter real-world study from Argentina.
    Gastroenterol Hepatol. 2024;47:253-261.
    PubMed     Abstract available
    
    
    February 2024
64. CALM A, Calafat M, Gonzalez-Munoza C, Canete F, et al
    Incidence of herpes zoster in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2024 Feb 3:S0210-5705(24)00032.
    PubMed     Abstract available
    
    
    
65. VARA-LUIZ F, Mendes I, Teles AE, Oliveira C, et al
    Malignant transformation in fistula after proctosigmoidectomy: A rare complication of longstanding Crohn's Disease.
    Gastroenterol Hepatol. 2024 Feb 3:S0210-5705(24)00033.
    PubMed    
    
    
    
66. PARRA V, Cifuentes S, Avendano S, de Leon EP, et al
    Real-world experience of vedolizumab use in Colombian patients with inflammatory bowel disease-EXVEDOCOL.
    Gastroenterol Hepatol. 2024 Feb 2:S0210-5705(24)00025.
    PubMed     Abstract available
    
    
    January 2024
67. DOMENECH E, Ciudin A, Balibrea JM, Coll EE, et al
    Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn's Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Span
    Gastroenterol Hepatol. 2024 Jan 28:S0210-5705(23)00502.
    PubMed     Abstract available
    
    
    
68. PEREZ JP, Ortiz JE, Franco Moreno AI, Plaza Santos MDR, et al
    Influence of HLA-DQA1 *05 on the loss of response to anti-TNF treatment in inflammatory bowel disease. Spanish cohort of real clinical practice.
    Gastroenterol Hepatol. 2024 Jan 22:S0210-5705(24)00020.
    PubMed    
    
    
    
69. DEZA DC, Julian Gomara AB, Biota EC, Beltran B, et al
    IMPACT OF MESALAZINE ON THE RESPONSE TO COVID-19 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. RESULTS OF A PROSPECTIVE MULTICENTRE STUDY OF GETECCU (VACOVEII STUDY).
    Gastroenterol Hepatol. 2024 Jan 12:S0210-5705(24)00017.
    PubMed     Abstract available
    
    
    
70. MOYA MC, Gismero FM, Ferrer CS, Hernandez-Camba A, et al
    Position Statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on Sexuality and Inflammatory Bowel Disease.
    Gastroenterol Hepatol. 2024 Jan 11:S0210-5705(24)00019.
    PubMed     Abstract available
    
    
    
71. BALDERRAMO D, Yamamoto-Furusho J, Ponce de Leon E, de Maria J, et al
    Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
    Gastroenterol Hepatol. 2024;47:51-62.
    PubMed     Abstract available
    
    
    
72. GRAU G, Altadill A, Brunet-Mas E, Calvet X, et al
    Cyclosporine treatment for severe steroid refractory immune-mediated colitis in a patient with ulcerative colitis.
    Gastroenterol Hepatol. 2024;47:72-73.
    PubMed    
    
    
    December 2023
73. NONES RB, Miranda EF, Nardi Marcal G, Barbosa Barauna FDS, et al
    Infliximab serum concentrations in luminal Crohn's Disease and its relationship with disease activity: a multicentric cross-sectional study.
    Gastroenterol Hepatol. 2023 Dec 29:S0210-5705(23)00505.
    PubMed     Abstract available
    
    
    
74. CALDERON P, Nunez P, Nos P, Quera R, et al
    Personalized therapy in inflammatory bowel disease.
    Gastroenterol Hepatol. 2023 Dec 13:S0210-5705(23)00497.
    PubMed     Abstract available
    
    
    
75. BASTIDA G, Alvarez-Sotomayor D, Aguas M, Iborra M, et al
    Evaluation of tolerance to mercaptopurine in patients with inflammatory bowel disease and gastrointestinal intolerance to azathioprine.
    Gastroenterol Hepatol. 2023 Dec 8:S0210-5705(23)00491.
    PubMed     Abstract available
    
    
    
76. GARCIA-ALANIS M, Toapanta-Yanchapaxi L, Reyes-Velasquez A, Mancilla F, et al
    The interrelation between anxiety and quality of life among patients with ulcerative colitis in remission.
    Gastroenterol Hepatol. 2023;46:747-753.
    PubMed     Abstract available
    
    
    November 2023
77. DEZA DC, Julian Gomara AB, Biota EC, Beltran B, et al
    A BOOSTER DOSE OF SARS-CoV-2 VACCINE IMPROVES SUBOPTIMAL SEROCONVERSION RATES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. RESULTS OF A PROSPECTIVE MULTICENTER STUDY OF GETECCU (VACOVEII STUDY).
    Gastroenterol Hepatol. 2023 Nov 23:S0210-5705(23)00474.
    PubMed     Abstract available
    
    
    
78. PENA MEJIA LA, Ruiz Nino GV, Arteta Cueto AA
    Relation between histopathological findings, clinical severity, and the need of surgery in patients with Crohn's disease.
    Gastroenterol Hepatol. 2023 Nov 23:S0210-5705(23)00473.
    PubMed     Abstract available
    
    
    
79. MANUEL BENITEZ J, Suarez-Ferrer C, Calafat M, Baston-Rey I, et al
    Paediatric to adult transition programme in inflammatory bowel disease, why do we need it?
    Gastroenterol Hepatol. 2023 Nov 15:S0210-5705(23)00469.
    PubMed    
    
    
    
80. GONZALEZ-MUNOZA C, Gely C, Gordillo J, Bertoletti F, et al
    Duration of smoking cessation in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2023 Nov 15:S0210-5705(23)00470.
    PubMed     Abstract available
    
    
    October 2023
81. SILVA ACV, Tumelero TJ, Yamamoto DR, Truppel SK, et al
    Biological therapy, surgery, and hospitalization rates for inflammatory bowel disease: an observational Latin American comparative study between adults and pediatric patients.
    Gastroenterol Hepatol. 2023 Oct 25:S0210-5705(23)00452.
    PubMed     Abstract available
    
    
    
82. IZQUIERDO VP, Frias-Ordonez JS, Cuadros C, Vargas M, et al
    Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian pediatric patients: Real world experience.
    Gastroenterol Hepatol. 2023 Oct 9:S0210-5705(23)00442.
    PubMed     Abstract available
    
    
    
83. PINERO G, Manosa M, Calafat M, Vayreda E, et al
    Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission.
    Gastroenterol Hepatol. 2023 Oct 6:S0210-5705(23)00439.
    PubMed     Abstract available
    
    
    
84. IZQUIERDO VP, Frias-Ordonez JS, Banos FJ, Cuadros C, et al
    Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: a case series study.
    Gastroenterol Hepatol. 2023 Oct 6:S0210-5705(23)00443.
    PubMed     Abstract available
    
    
    
85. LAO DOMINGUEZ FA, Fobelo Lozano MJ, Gutierrez Pizarraya A, Castro Fernandez M, et al
    Relationship between ustekinumab trough concentrations and both clinical and biological remission in patients with Crohn's disease.
    Gastroenterol Hepatol. 2023;46:631-632.
    PubMed    
    
    
    
86. FORTUNY M, Gutierrez-Rios L, Vayreda E, Manosa M, et al
    Tofacitinib for the treatment of inflammatory condition of the ileoanal pouch refractory to infliximab.
    Gastroenterol Hepatol. 2023;46:629-630.
    PubMed    
    
    
    August 2023
87. SERRANO DIAZ L, Iniesta Navalon C, Gomez Espin R, Nicolas De Prado I, et al
    Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study.
    Gastroenterol Hepatol. 2023 Aug 18:S0210-5705(23)00392.
    PubMed     Abstract available
    
    
    
88. RIOS LG, Vayreda E, Calafat M, Canete F, et al
    Changes in the intensified regimen of infliximab in patients with inflammatory bowel disease in sustained remission. Reflections on a series of cases.
    Gastroenterol Hepatol. 2023 Aug 8:S0210-5705(23)00374.
    PubMed    
    
    
    
89. ARENAS A, Moreta MJ, Ordas I, Fernandez-Clotet A, et al
    De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice.
    Gastroenterol Hepatol. 2023 Aug 8:S0210-5705(23)00376.
    PubMed     Abstract available
    
    
    
90. DIAZ LS, Navalon CI, Espin RG, Prado IN, et al
    Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2023;46:504-511.
    PubMed     Abstract available
    
    
    June 2023
91. SUAREZ FERRER C, Martin-Arranz MD, Martin-Arranz E, Rodriguez Morata F, et al
    Current management of bowel failure due to Crohn's disease in Spain: Results of a GETECCU survey.
    Gastroenterol Hepatol. 2023;46:439-445.
    PubMed     Abstract available
    
    
    
92. NAVARRO-CORREAL E, Ibarz Casas A, Agustino Rodriguez S, Marin L, et al
    Knowledge, attitudes and behaviours on smoking cessation in nurses caring for patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2023;46:468-471.
    PubMed    
    
    
    May 2023
93. BENITO BM, Gisbert JP, Garcia Fraile Fraile LJ, Blandino AB, et al
    SEXUALLY TRANSMITTED INFECTIONS AS A DIFFERENTIAL DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2023 May 5:S0210-5705(23)00333.
    PubMed    
    
    
    
94. GONZALEZ-MARTINEZ A, Garcia IM, Quintas S, Chaparro M, et al
    Headache in patients with inflammatory bowel disease: Migraine prevalence according to the Migraine Screening-Questionnaire (MS-Q) and headache characteristics.
    Gastroenterol Hepatol. 2023 May 4:S0210-5705(23)00331.
    PubMed     Abstract available
    
    
    
95. MENG XF, Lin QY, Yin HL, Li ZQ, et al
    Magnetic resonance imaging for evaluation of bowel inflammation and disease activity in Crohn's disease: A systematic review and meta-analysis.
    Gastroenterol Hepatol. 2023;46:336-349.
    PubMed     Abstract available
    
    
    April 2023
96. PITARCH LG, Almela P, Nos P
    Leishmania infection in patients with Inflammatory Bowel Disease: case series and literature review.
    Gastroenterol Hepatol. 2023 Apr 13:S0210-5705(23)00074.
    PubMed     Abstract available
    
    
    
97. MORENO EN, Lopez Gonzalez J, Saez ML
    METASTATIC CROHN'S DISEASE WITH ESPLENIC AFECTATION: A VERY RARE CASE.
    Gastroenterol Hepatol. 2023 Apr 4:S0210-5705(23)00073.
    PubMed    
    
    
    
98. GARGALLO-PUYUELO CJ, Garcia-Mateo S, Martinez-Dominguez SJ, Gomollon F, et al
    Is the gender or age of the physician key to a good physician-patient with inflammatory bowel disease relationship?
    Gastroenterol Hepatol. 2023;46:261-265.
    PubMed     Abstract available
    
    
    
99. RAMOS L, Carrillo-Palau M, Alonso-Abreu I, Reygosa C, et al
    COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desire.
    Gastroenterol Hepatol. 2023;46:255-260.
    PubMed     Abstract available
    
    
    March 2023
100. CASTILLO-REGALADO E, Rios R, Arajol C, Gely C, et al
     Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy.
     Gastroenterol Hepatol. 2023;46:164-170.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.